Virax Biolabs Group Limited (VRAX)

Revenue by Segment

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Distribution of Diagnostics Test Kits and PPE Products	12.42K	6.33K	156.42K	8.56K		123.82K
Distribution of Diagnostics Test Kits and PPE Products Growth	96.22%	-95.95%	1727.11%	-		23.97%
Total	12.42K	6.33K	156.42K	8.56K		123.82K
Total Growth	96.22%	-95.95%	1727.11%	-		23.97%

Revenue by Geography

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
United Kingdom	12.42K	6.33K	156.42K	8.56K		123.82K
United Kingdom Growth	96.22%	-95.95%	1727.11%	-		23.97%
Total	12.42K	6.33K	156.42K	8.56K		123.82K
Total Growth	96.22%	-95.95%	1727.11%	-		23.97%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 19, 2026

Data Sources Report a data error